AC Immune (ACIU) Net Cash Flow (2015 - 2025)

AC Immune (ACIU) has 11 years of Net Cash Flow data on file, last reported at -$909600.4 in Q4 2025.

• On a quarterly basis, Net Cash Flow fell 141.7% year-over-year to -$909600.4 in Q4 2025; TTM through Mar 2026 was $10.8 million, a 128.43% increase from a year earlier, with the FY2025 full-year figure at -$10.2 million, up 78.0% from the prior year.
• Net Cash Flow for Q4 2025 stood at -$909600.4, down from $2.4 million in the prior quarter.
• Over the last five years, Net Cash Flow for ACIU reached as high as $54.0 million in Q4 2023 and fell as low as -$51.0 million in Q2 2021.
• Historically, Net Cash Flow has averaged -$7.1 million across 5 years, with a median of -$11.5 million in 2021.
• Across the five-year window, Net Cash Flow slumped 1574.73% in 2021 and jumped 514.42% in 2023, its largest moves.
• Year by year, Net Cash Flow stood at -$12.1 million in 2021, then retreated by 7.79% to -$13.0 million in 2022, then soared by 514.42% to $54.0 million in 2023, then tumbled by 95.96% to $2.2 million in 2024, then plunged by 141.7% to -$909600.4 in 2025.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$909600.4 in Q4 2025, $2.4 million in Q3 2025, and $9.3 million in Q2 2025.